Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) - Tolaney, S M; Barry, W T; Guo, H (J Clin Oncol, 2017)